Key result
Preadmission statins, NSAIDs, or glucocorticoids fail to reduce post-ICU depression or anxiety risk.
Why the study?
The risk of depression and anxiety is elevated after intensive care, and drugs with anti-inflammatory properties may have antidepressant and anxiolytic effects. This study investigated the association between preadmission anti-inflammatory drug use and the risk of new-onset depression and anxiety among adult ICU patients.
Does preadmission use of anti-inflammatory drugs reduce the risk of new-onset depression and anxiety in adult ICU patients receiving mechanical ventilation?
Cohort (n=48,207)
Yes
Does preadmission use of anti-inflammatory drugs reduce the risk of new-onset depression and anxiety in adult ICU patients receiving mechanical ventilation?
Preadmission use of anti-inflammatory drugs, including statins, NSAIDs, and glucocorticoids, does not alter the risk of developing depression or anxiety after critical illness requiring mechanical ventilation.
Does not support changing anti-inflammatory prescribing to mitigate post-critical illness depression or anxiety; leaves open effects for randomized trials.
Objectives: Risk of depression and anxiety is elevated after intensive care. Drugs with anti-inflammatory properties may have antidepressant and anxiolytic effects. The aim of this study was to investigate the association between preadmission use of drugs with anti-inflammatory effects and risk of new-onset depression and anxiety among adult patients admitted to an ICU. Design: Propensity score–matched, population-based cohort study. Setting: All ICUs in Denmark from 2005 to 2013. Patients: Adults receiving mechanical ventilation in an ICU. Interventions: None. Measurements and Main Results: A total of 48,207 ICU patients were included. Exposures were preadmission single-agent or combined use of statins, nonsteroidal anti-inflammatory drugs, or glucocorticoids. Outcomes were cumulative incidence (risk) and risk ratio of new-onset psychiatrist-diagnosed depression or anxiety or prescriptions for antidepressants or anxiolytics. Propensity score matching yielded 6,088 statin user pairs, 2,886 nonsteroidal anti-inflammatory drug user pairs, 1,440 glucocorticoid user pairs, and 1,743 combination drug user pairs. The cumulative incidence of anxiety and depression during the 3 years following intensive care was 18.0% (95% CI, 17.0–19.0%) for statin users, 21.3% (95% CI, 19.8–22.9%) for nonsteroidal anti-inflammatory drug users, 17.4% (95% CI, 15.4–19.5%) for glucocorticoid users, and 19.0% (95% CI, 16.3–20.2%) for combination users. The cumulative incidence was similar in nonusers compared with users in all drug groups. The risk ratio of depression and anxiety 3 years after admission to ICU was 1.04 (95% CI, 0.96–1.13) for statin users, 1.00 (95% CI, 0.90–1.11) for nonsteroidal anti-inflammatory drug users, 0.97 (95% CI, 0.82–1.14) for glucocorticoid users, and 1.05 (95% CI, 0.90–1.21) for combination users, compared with nonusers. Results were consistent across subgroups (gender, age, preadmission diseases, type of admission) and sensitivity analyses (depression and anxiety separately). Conclusions: Preadmission use of statins, nonsteroidal anti-inflammatory drugs, glucocorticoids, or combinations did not alter the risk of depression and anxiety after critical illness.
No takes yet. Share an insight, caveat, or question.
Medici et al. (2017) conducted a cohort in Critical illness requiring mechanical ventilation in an ICU (n=48,207). Preadmission anti-inflammatory drugs (statins, NSAIDs, glucocorticoids, or combinations) vs. Nonusers was evaluated on New-onset psychiatrist-diagnosed depression or anxiety or prescriptions for antidepressants or anxiolytics at 3 years (RR 1.04, 95% CI 0.96-1.13). Preadmission use of statins (RR 1.04; 95% CI 0.96-1.13), NSAIDs (RR 1.00), or glucocorticoids (RR 0.97) did not alter 3-year risk of depression or anxiety after ICU admission.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: